Ferguson-Guerra DE, Sánchez-Guerrero SA

Language: Spanish
References: 29
Page: 183-191
PDF size: 115.38 Kb.

ABSTRACT

Background: The most frequently used methods to obtain leukodepletion in red blood cell transfusion are: buffy-coat removal, washed red blood cells and leukoreduction by either bedside or prestorage filtration. Currently, filters are of 3^rd and 4^th generation with an effectiveness of 99.90 and 99.99% of leukocyte depletion, according to international standards, preventing primary alloimmunization to histocompatibility leukocyte antigens (HLA), reducing the non-hemolytic febrile transfusion reactions and the transmission of cytomegalovirus risks. Methods: We studied 96 red cell units; 48 obtained by the top and bottom system and then filtered with 4 different filters (12 units with each one). Residual leukocytes were counted by flow cytometry, and we determined red cell recovery and filtration time. The same parameters were evaluated in other 48 units obtained by the conventional system, without buffy coat removal. Results: We found results concordant with the American Association of Blood Banks (AABB) standards using any of the four filters, although there were some differencies between them; observing a better leukoreduction in the first group , but without statistical significance (p › 0.05). Conclusions: As the studies about leukoreduction continue, it becomes more important to evaluate those filters that we use as well as the factors that influence the process. In this study we controlled the temperature, time of storage, random selection of units, and flow cytometry processes. However, we could not find any statistical difference between the filters in any of the analized parameters.

REFERENCES

1. International Forum. Universal leucocyte-depletion of blood components: cell concentrates and plasma, Vox Sang 2001; 81: 56-77.

2. Young J. Component Preparation. In: Rudmann S. Textbook of blood banking and transfusion medicine. Philadelphia: WB Saunders Company, 1994; pp. 235-239.

3. Radillo GA. Medicina transfusional. México: Editorial Prado, 1999; pp. 409-418.

4. Williamson L. Production and storage of blood components. In: Murphy M, Pamphilon D. Practical transfusion medicine. Cambridge, Mass: Blackwell Science, 2001; pp. 231-234.

5. Dzik WH. Leukoreduced products. In: Hillyer C, Hillyer K, Strobl F, Jefferies L. Handbook of transfusion medicine. San Diego: Academic Press, 2001; pp. 125-128.

6. Bravo-Lindoro AG. Leucorreducción. ¿Para qué? ¿Cuándo? ¿Cómo? Gac Med Mex 2002; 138 (supl 1): 540-543.

7. van de Watering B: Clinical significance of leukoreduction of blood components. Vox Sang 2000; 78 (suppl 2): 227.

8. Triulzi DJ. Blood transfusion therapy, a physician’s handbook. 6th ed. Bethesda, Maryland: AABB Press, 1999; pp. 10-12.

9. Dzik WH. Leukoreduction of blood components. Curr Opin Hematol 2002; 9 (6): 521-526.

10. Malagón-Martínez A. Consenso Nacional para el Uso de Sangre y sus Componentes. Gac Med Mex 2002; 138 (supl 1): S35-S37.

11. Technical Manual. 13th ed. Bethesda, Maryland: AABB Press, 1999; pp. 461-462.

12. Rivera LR. Indicaciones clínicas de la transfusión sanguínea, empleo de los componentes leucorreducidos. En: Tópicos selectos de medicina transfusional. México: Editorial Prado, 2002; pp. 109-114.

13. Bautista JJ. Leucorreducción prealmacenamiento y su control de calidad. En: Tópicos selectos de medicina transfusional. México: Editorial Prado, 2002; pp. 115-120.

14. Blajchamn M, Goldman M. Proceedings of a Consensus Conference: Prevention of post-transfusion CMV in the era of universal leukoreduction. Transf Med Rev 2001; 15: 1-20.

15. Vamvkas, E, Blajchman, M, Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. Transf Med Rev 2000; 14: 23-33.

16. Blajchman MA. Immunomodulation and blood transfusion. Am J Ther 2002; 9: 389-395.

17. Zucker-Franklin D, Poncake BA. White cell reduction by filtration may significantly decrease human T-lymphotropic virus type 1 Tax-encoded proteins in blood used for transfusion. Transfusion 1998; 38: 317.

18. Velasco SG, Wisniewski PM. Probabilidad y estadística para ingeniería y ciencias. México: Ed Thomson Learning, 2001; pp. 223, 734-573.

19. Ley General de Salud, tomo I, Título Quinto, art 96. 16a ed. México: Editorial Porrúa, 2000; pp. 18-19.

20. Dzik S, Aubuchon J. Leukocyte reduction of blood components: Public policy and new technology. Trans Med Rev 2000; 14: 34-52.

21. Dzik WH. Leukocyte counting during process control of leukoreduced blood components. Vox Sang 2000; 78 (suppl 2): 223.

22. Kao KJ. Mechanisms and New Approaches for the Allogeneic Blood Transfusion-Induced Immunomodulatory Effects. Transf Med Rev 2000; 14: 12-22.

23. Guidance for Industry. Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion. Food and Drug Administration, January, 2001; pp. 3, 7, 8, 11.

24. Sivakkumaran M, Saunders P. Effect of storage time on filter performance. Transfusion 2001; 41: 300.

25. Hamasaki N, Yamamoto M. Red blood cell function and blood storage. Vox Sang 2000; 79: 191-197.

26. 26, Abd El-hamid AS, Eskander FG. Evaluation of the pre-storage leukocyte depletion by buffy coat removal by centrifugation in transfusion practice. Blood 1999; 94: 116b.

27. Norma Oficial Mexicana NOM-003-SSA2-1993 “Para la Disposición de Sangre Humana y sus Componentes con fines Terapéuticos”, 3.1.6, p. 13.

28. Dumont LS, Dzik WH, Rebulla P, Brandwin H. Practical guidelines for process validation and process control of white cell-reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Transfusion 1996; 36: 11-20.

29. Hébert PC, Fergusson DA. Evaluation of a universal leukoreduction program in Canada. Vox Sang 2002; 83 (suppl 1): 207-209.